Canakinumab for Schnitzler syndrome

Canakinumab is in clinical development for the treatment of adults with Schnitzler syndrome. Schnitzler syndrome is a rare inflammatory condition. The exact underlying cause is currently unknown, however certain proteins of the immune system (including cytokines) play a role in the development of the inflammation in Schnitzler syndrome. The first clinical sign of this condition is usually a mildly or non-itchy skin rash; other symptoms include fevers, joint pain and inflammation, enlarged internal organs, bone pain and muscle aches. There are currently no approved treatments for Schnitzler syndrome.